2024-10-20 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis Report

**1. Performance Comparison:**

AbbVie Inc (ABBV) has outperformed the S&P 500 (VOO) over the period considered. The cumulative return for ABBV is 145.47%, while the S&P 500 has returned 137.88%, resulting in a **positive divergence of 7.59**. This positive divergence puts ABBV's performance in the **49.86 percentile** compared to its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

The current closing price of ABBV is **$188.86**. This price is slightly below the **5-day moving average of $191.08**, indicating potential downward pressure.  However, the stock remains above the **20-day moving average ($193.61)** and the **60-day moving average ($193.03)**, suggesting some support. 

**3. Technical Indicators:**

* **RSI (23.77):**  The RSI suggests that ABBV is currently in **oversold territory**, potentially signaling a potential rebound.
* **PPO (-0.41):** The PPO indicates a **weak short-term trend**, reinforcing the oversold signal from the RSI.
* **Delta_Previous_Relative_Divergence (-11.0):** The negative value suggests a **recent decline in relative performance** compared to the S&P 500.
* **Expected_Return (5.45%):** ABBV has a positive expected return compared to the S&P 500, implying a potential for long-term outperformance.

**4. Recent Earnings & Outlook:**

* **Latest Earnings:** ABBV's latest earnings were reported on **2024-07-25** with an **EPS of 2.65, beating the estimated EPS of 2.57**. 
* **Overall Performance:** ABBV has consistently exceeded EPS estimates in the past five quarters, demonstrating strong earnings performance.
* **Outlook:** ABBV continues to show robust earnings growth and remains well-positioned in its pharmaceutical market. 

**5. News & Recent Issues:**

**Recent Market Outlook:** ABBV is considered a strong and stable player in the pharmaceutical industry. The stock is often mentioned as a potential buy by analysts, given its strong fundamentals and dividend yield.

**Analyst Opinions:**  Most analysts are bullish on ABBV, citing its strong earnings performance, robust pipeline of new drugs, and dividend stability. 

**Performance Highlights:** ABBV's strong performance in the recent earnings season has bolstered investor confidence, contributing to the stock's resilience in a volatile market. 

**6. Summary:**

ABBV has consistently outperformed the S&P 500, displaying strong earnings growth and positive long-term prospects. Recent price action suggests a potential pullback, but technical indicators highlight oversold conditions, hinting at a potential rebound. The stock remains attractive for long-term investors due to its consistent earnings performance and positive outlook.

**7. Conclusion:**

Overall, ABBV appears to be a solid investment with a positive outlook. While the stock may experience short-term fluctuations, its long-term growth potential remains promising. However, investors should remain aware of potential market risks and monitor the company's performance closely.
